Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Nathan

Showing results (61-70 of 129) with videos related to

Pageof 13
Sort By:
BMJ Oncology|January 31, 2025
Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trialMatthew Tucker, Yu-Wei Chen, Martin H Voss, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2019
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanomaCaroline Robert, Keith Flaherty, Paul Nathan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2022
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal MelanomaRichard D Carvajal, Paul Nathan, Joseph J Sacco, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage IIIJean Jacques Grob, Dirk Schadendorf, Paul Lorigan, et al.
Journal of Cancer Survivorship : Research and Practice|August 30, 2021
Future research in cancer survivorshipRaymond J Chan, Larissa Nekhlyudov, Saskia F A Duijts, et al.
European Journal of Endocrinology|June 9, 2020
Clinical considerations for the treatment of secondary differentiated thyroid carcinoma in childhood cancer survivorsHanneke M van Santen, Erik K Alexander, Scott A Rivkees, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2012
Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancerPaul Nathan, Martin Zweifel, Anwar R Padhani, et al.
International Journal of Cancer|August 2, 2014
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virusJi-Li Chen, Amina Dawoodji, Andrea Tarlton, et al.
Cancers|December 30, 2025
Specialist Neurology Involvement and Impact in Immune Checkpoint Inhibitor-Related Neurotoxicity: Experience in a Unified Healthcare SystemBenjamin Schroeder, Prakrit Prasad, Ope Gbadegesin, et al.
Cell Reports. Medicine|April 16, 2025
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecificJoseph J Sacco, Peter Kirk, Emma Leach, et al.
Pageof 13

Showing results (61-70 of 129) with videos related to

Sort By:
Pageof 13
BMJ Oncology|January 31, 2025
Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trialMatthew Tucker, Yu-Wei Chen, Martin H Voss, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2019
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanomaCaroline Robert, Keith Flaherty, Paul Nathan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2022
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal MelanomaRichard D Carvajal, Paul Nathan, Joseph J Sacco, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage IIIJean Jacques Grob, Dirk Schadendorf, Paul Lorigan, et al.
Journal of Cancer Survivorship : Research and Practice|August 30, 2021
Future research in cancer survivorshipRaymond J Chan, Larissa Nekhlyudov, Saskia F A Duijts, et al.
European Journal of Endocrinology|June 9, 2020
Clinical considerations for the treatment of secondary differentiated thyroid carcinoma in childhood cancer survivorsHanneke M van Santen, Erik K Alexander, Scott A Rivkees, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2012
Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancerPaul Nathan, Martin Zweifel, Anwar R Padhani, et al.
International Journal of Cancer|August 2, 2014
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virusJi-Li Chen, Amina Dawoodji, Andrea Tarlton, et al.
Cancers|December 30, 2025
Specialist Neurology Involvement and Impact in Immune Checkpoint Inhibitor-Related Neurotoxicity: Experience in a Unified Healthcare SystemBenjamin Schroeder, Prakrit Prasad, Ope Gbadegesin, et al.
Cell Reports. Medicine|April 16, 2025
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecificJoseph J Sacco, Peter Kirk, Emma Leach, et al.
Pageof 13